Literature DB >> 29769873

Hepatitis C surveillance in Canada.

E Payne1, S Totten1, C Archibald1.   

Abstract

BACKGROUND: Hepatitis C is a highly transmissible virus that can lead to chronic liver disease. It continues to be a major public health concern in Canada.
OBJECTIVE: To describe surveillance trends of reported cases of Hepatitis C virus (HCV) in Canada by age and sex from 1991-2012.
METHODS: Cases of HCV reported to the Canadian Notifiable Disease Surveillance System were compiled at the national level. As most reported cases are not differentiated by acute or chronic HCV infection status, presented results are based on total HCV cases. Time trends are provided from 1991-2012, with a more detailed examination of age and sex patterns from 2005-2012.
RESULTS: The rate of reported HCV infection increased sharply from 1991 (the year it was first notifiable) until 1998, when the highest overall rate of 66.9 per 100,000 was observed. From that time until 2012, rates of reported cases decreased in both sexes, but remained consistently higher among males than females. In 2012, the overall rate of reported HCV infection was 29.3 per 100,000. In younger age groups, rates among females were marginally higher, while males in older age groups (30 and above) exhibited substantially higher rates.
CONCLUSION: This surveillance summary presents the longer-term trends in reported cases and corresponding rates of HCV in Canada using national surveillance data. Canada continues to experience a downward trend in HCV rates; however, the burden of infection will continue to increase as chronically infected individuals develop severe illness.

Entities:  

Year:  2014        PMID: 29769873      PMCID: PMC5864481          DOI: 10.14745/ccdr.v40i19a01

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  17 in total

1.  Canadian trends in cancer prevalence.

Authors:  Larry F Ellison; Kathryn Wilkins
Journal:  Health Rep       Date:  2012-03       Impact factor: 4.796

Review 2.  Direct-acting antiviral agents for hepatitis C virus infection.

Authors:  Jennifer J Kiser; Charles Flexner
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-11-05       Impact factor: 13.820

Review 3.  A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

4.  Seroprevalence of hepatitis B and C virus infections: Results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey.

Authors:  Michelle Rotermann; Kellie Langlois; Anton Andonov; Maxim Trubnikov
Journal:  Health Rep       Date:  2013-11       Impact factor: 4.796

5.  Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): an age-period-cohort analysis.

Authors:  Max Trubnikov; Ping Yan; Jane Njihia; Chris Archibald
Journal:  CMAJ Open       Date:  2014-10-01

6.  The prevalence and correlates of hepatitis C virus (HCV) infection and HCV-HIV co-infection in a community sample of gay and bisexual men.

Authors:  Ted Myers; Dan Allman; Kunyong Xu; Robert S Remis; Jeffrey Aguinaldo; Ann Burchell; Liviana Calzavara; Carol Swantee
Journal:  Int J Infect Dis       Date:  2009-01-30       Impact factor: 3.623

7.  Management of chronic hepatitis C: consensus guidelines.

Authors:  Morris Sherman; Stephen Shafran; Kelly Burak; Karen Doucette; Winnie Wong; Nigel Girgrah; Eric Yoshida; Eberhard Renner; Philip Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

8.  Genetic factors in mother-to-child transmission of HCV infection.

Authors:  Elena Bevilacqua; Annalisa Fabris; Paolo Floreano; Lucy Pembrey; Marie-Louise Newell; Pier-Angelo Tovo; Antonio Amoroso
Journal:  Virology       Date:  2009-05-29       Impact factor: 3.616

9.  Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand.

Authors:  Nicole Ngo-Giang-Huong; Gonzague Jourdain; Wasna Sirirungsi; Luc Decker; Woottichai Khamduang; Sophie Le Coeur; Surat Sirinontakan; Rosalin Somsamai; Karin Pagdi; Jittapol Hemvuttiphan; Kenneth McIntosh; Francis Barin; Marc Lallemant
Journal:  Int J Infect Dis       Date:  2010-01-03       Impact factor: 3.623

10.  Estimated prevalence of Hepatitis C Virus infection in Canada, 2011.

Authors:  M Trubnikov; P Yan; C Archibald
Journal:  Can Commun Dis Rep       Date:  2014-12-18
View more
  4 in total

1.  The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.

Authors:  Hemant Shah; Marc Bilodeau; Kelly W Burak; Curtis Cooper; Marina Klein; Alnoor Ramji; Dan Smyth; Jordan J Feld
Journal:  CMAJ       Date:  2018-06-04       Impact factor: 8.262

2.  Surveillance summary reporting guide.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2015-04-02

3.  Descriptive epidemiology of hepatitis C in individuals referred for specialized HCV care in Newfoundland and Labrador, 1996-2014.

Authors:  Mary Malebranche; Dawn King; Jennifer Leonard
Journal:  Can Liver J       Date:  2018-10-03

4.  HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study.

Authors:  Curtis L Cooper; Chrissi Galanakis; Jessy Donelle; Jeff Kwong; Rob Boyd; Lisa Boucher; Claire E Kendall
Journal:  BMC Infect Dis       Date:  2019-08-23       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.